- Conditions
- Urinary Tract Urothelial Carcinoma
- Interventions
- Sunitinib
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Ann Arbor, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–768
of 919
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hysterectomy
- Interventions
- Peritoneal washings
- Diagnostic Test
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Not listed
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Morrisville, North Carolina
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Interventions
- Etoposide; Oral, 50 Mg, Focused ultrasound with neuro-navigator-controlled sonication
- Drug · Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer
- Interventions
- denosumab, Surgery
- Biological · Procedure
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Carcinoma, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Recurrent Breast Carcinoma
- Interventions
- Best Practice, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration, Supportive Care
- Other · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Interventions
- Enfortumab Vedotin, Pembrolizumab, Intensity Modulated Radiation Therapy (IMRT), Transurethral Resection of Bladder Tumor, Cystoscopy (CS), Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET)
- Drug · Biological · Radiation + 1 more
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Head and Neck Cancer
- Interventions
- Standard Care Chemoradiation
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- Akt Inhibitor MK2206, Anastrozole, Goserelin Acetate, Laboratory Biomarker Analysis, Neoadjuvant Therapy, Pharmacological Study, Therapeutic Conventional Surgery
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Chicago, Illinois • Iowa City, Iowa + 5 more
- Conditions
- Breast Cancer
- Interventions
- HER-2 pulsed Dendritic Cell Vaccine
- Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Benign Prostatic Hyperplasia
- Interventions
- TULSA Procedure
- Device
- Lead sponsor
- Profound Medical Inc.
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2061
- U.S. locations
- 5
- States / cities
- West Hills, California • Jacksonville, Florida • York, Pennsylvania + 2 more
- Conditions
- Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma
- Interventions
- Bevacizumab, Everolimus, Laboratory Biomarker Analysis, Pegylated Liposomal Doxorubicin Hydrochloride
- Biological · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- CT, 18F-FLT, PET
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 27
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more
- Conditions
- Fibroid Uterus, Abnormal Uterine Bleeding, Myoma;Uterus
- Interventions
- Tranexamic Acid, Placebos
- Drug
- Lead sponsor
- Eastern Virginia Medical School
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Elizabeth, New Jersey • Hamilton, New Jersey • Livingston, New Jersey + 4 more
- Conditions
- Penile Cancer
- Interventions
- Quality of Life Questionnaires, Patient Educational Needs, Symptom Management
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8
- Interventions
- Educational Intervention, Text Message-based Navigation Intervention, Motivational Interviewing, Best Practice, Questionnaire Administration, Quality-of-Life Assessment
- Other · Behavioral
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 526
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 406 more
- Conditions
- Bladder Cancer
- Interventions
- sunitinib malate
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Bladder Cancer
- Interventions
- FDG PET/MR
- Procedure
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy), Non-muscle Invasive Bladder Cancer (NMIBC), Non-Muscle Invasive Bladder Neoplasms, Non-muscle Invasive Bladder Cancer, Bladder Cancer (BC), Transurethral Resection of Bladdertumors, Transurethral Resection of the Bladder, Non-Muscle Invasive Bladder Carcinoma
- Interventions
- HISA
- Device
- Lead sponsor
- CAMC Health System
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Charleston, West Virginia
- Conditions
- Breast Cancer
- Interventions
- anastrozole, Placebo
- Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Astrocytoma, Breast Carcinoma Metastatic in the Brain, Glioma, Invasive Breast Carcinoma, Oligodendroglioma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Glioma
- Interventions
- Best Practice, Ketoconazole
- Other · Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- NMIBC, MIBC, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer
- Interventions
- This is a non-interventional, observational, prospective study.
- Other
- Lead sponsor
- Bladder Cancer Advocacy Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Breast Cancer, Invasive Adenocarcinoma of the Breast
- Interventions
- Cryoablation, Ipilimumab
- Procedure · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York